☰

Empresas y finanzas

BIO-Europe Spring 2008 Exhibitor Profiles


    BIO-Europe Spring 2008 takes place April 7-9, 2008 in Palacio
    Municipal de Congresos, Madrid, Spain. Listed below are profiles from
    BIO-Europe Spring 2008 exhibitors.

    For in-depth information about the BIO-Europe Spring 2008, please
    visit http://www.ebdgroup.com/bes/index.htm.

    Business Wire is the official news wire service BIO-Europe Spring
    2008. Breaking news releases and photos are available at
    http://www.tradeshownews.com, Business Wire´s trade show, conference,
    and event news resource.

    -0-
    *T
    Company: Allon Therapeutics Inc.
    Booth/Stand: Presenting Company
    Ticker Symbol & Exchange: NPC: TSE
    Media Contact: Aaron Keay
    Phone: 604 742 2540
    E-mail: akeay@allontherapeutics.com
    Web: www.allontherapeutics.com

    Allon Therapeutics Inc. is a clinical-stage biotechnology company
    developing treatments for major neurodegenerative conditions. In Q1
    2008, Allon´s drug AL-108 demonstrated robust human efficacy in
    amnestic Mild Cognitive Impairment, a precursor to Alzheimer´s
    disease. A Phase IIb trial in Alzheimer´s disease will begin in 2008.
    Additional Phase II human efficacy trials will be completed and
    results reported in 2008 on the Company´s schizophrenia and
    intravenous delivery programs. The Company is listed on the Toronto
    Stock Exchange under the trading symbol "NPC" (Neuroprotection
    Company(TM)) and based in Vancouver. For additional information
    please visit the Company´s website: www.allontherapeutics.com.

    Company: Cellerix S.A.
    Media Contact: Dr. Maria Pascual
    Phone: 34 91 8049264
    E-mail: mpascual@cellerix.com
    Web: www.cellerix.com

    Cellerix is a recognized leader in the research and application of
    expanded cells of adult origin, with an advanced clinical stage
    pipeline: Its lead product candidate, Ontaril(R), currently in Phase
    III trial, is being developed for the treatment of complex perianal
    fistulas. In previous trials Ontaril(R) demonstrated efficacy greater
    than 70%. North American rights have been licensed to Axcan Pharma.

    A second product is a chimeric skin currently being developed for the
    treatment of Epidermolysis Bullosa and is in phase II trials.

    Cellerix is also developing a new generation of products based on
    allogeneic stem cells, which are currently undergoing preclinical
    development.

    The Company wants to firmly establish itself as a world leading
    biopharmaceutical company in the field of cell therapy over the next
    years.

    Company: Debiopharm Group
    Media Contact: Jo-Anne Lutjens
    Phone: 41 (0)21 321 01 11
    E-mail: jalutjens@debiopharm.com
    Web: www.debiopharm.com

    Debiopharm Group is a global biopharmaceutical development specialist
    that in-licenses promising biologics and small molecule drug
    candidates. Debiopharm develops its products for global registration
    and maximum commercial potential for out-licensing to pharmaceutical
    partners for sales and marketing.

    Debiopharm independently funds the worldwide development of all of its
    products while providing expertise in pre-clinical and clinical
    trials, manufacturing, drug delivery and formulation, and regulatory
    affairs.

    Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm
    has developed three products with global combined sales in excess of
    $2.65 billion in 2007.

    For more information on Debiopharm Group, please visit:
    www.debiopharm.com.

    Company: EOS (Ethical Oncology Science) S.p.A.
    Phone: 39 02 87391608
    E-mail: segreteria@eosmilano.com
    Web: www.eosmilano.com

    EOS (Ethical Oncology Science) has been founded by a lean team of bio-
    entrepreneurs to advance ethical projects with strong scientific
    rationale that can ultimately help people with cancer. EOS mission is
    to seek out and help realize the commercial potential of novel
    research programs based on sound science that can progress cancer
    treatment.

    EOS is building a portfolio of oncology projects through in-licensing
    and own development, primarily including targeted therapy with focus
    on achieving best in class novel agents. EOS partnering vision is to
    take the lead or co-lead in development, to assume the investment
    risk, and to share with originators the value generated by advancing
    programs up to clinical proof of concept (POC). This is where value
    for investors and partners is being created.

    Company: FGK Clinical Research GmbH
    Booth/Stand: 31 a
    Media Contact: Dr. Edgar J. Fenzl
    Phone: 49 - 89 - 893119-0
    E-mail: edgar.fenzl@fgk-cro.de
    Web: www.fgk-cro.de

    As a contract research organization FGK provides a wide range of
    services in drug and medical device development, from early
    conception, until final report (statistical consulting, project
    management, monitoring, data management, statistical analysis,
    medical writing). FGK has a focus on biotech companies which need
    more support and consulting in the clinical drug development process
    than pharmaceutical companies. In detail, services offered include: *
    Phase II-IV trials * Post marketing surveillance; and special
    services such as * Pharmacovigilance * Quality of life * Reviews *
    Expert reports and * Organization of Opinion-Leader Meetings.

    Company: FINA BIOTECH
    Phone: 34917991564
    E-mail: jm_esteban@finabiotech.es
    Web: www.finabiotech.es

    Fina Biotech is a biotechnology company that is investing in
    autologous adult stem cells projects, anticancer drugs and kit for
    the diagnosis and prognosis in cancer and cardiovascular diseases.
    Several products are ready to sell or in the final stages of clinical
    validation or clinical trials. We are looking for licensing out our
    products including the right for production and sales. For more
    information please contact Mr. Jose M. Esteban, the Sales Manager

    Company: IDA Ireland
    Booth/Stand: 6
    Media Contact: Raffaella Harvey
    Phone: 33 1 43 12 91 80
    E-mail: raffaella.harvey@ida.ie
    Web: www.idaireland.com

    IDA Ireland is responsible for the development of FDI and the
    provision of unparalleled support to over 1000 international
    companies in Ireland. The Biopharmaceutical industry is one of IDA
    Ireland´s most valuable sectors with exports worth EUR 43 bn p.a.
    employing over 20,000. With 9 of the top 10 companies worldwide now
    being based in Ireland (notably Pfizer, Novartis and Wyeth), IDA
    Ireland has successfully contributed to the dynamic growth of the
    industry (ie: EUR 470mn R&D investments in 2006). IDA Ireland looks
    forward to meeting investors wishing to benefit from Ireland´s
    favourable tax regime, subsidies, high-calibre pools of labour and
    pro-business attitude.

    Company: Silence Therapeutics plc / AG
    Ticker Symbol & Exchange: SLN & LSE, listed on AIM
    Media Contact: Mr. Thomas Christely
    Phone: 0049 30 9489 2800
    E-mail: t.christely@silence-therapeutics.com
    Web: www.silence-therapeutics.com

    Silence Therapeutics plc (LSE:SLN) is a leading RNAi therapeutics
    company, based in London, UK, and Berlin, Germany and listed on AIM.
    Silence Therapeutics has developed novel, proprietary short
    interfering RNA ("siRNA") molecules, ("AtuRNAi"), and a proprietary
    systemic delivery system ("AtuPLEX"). In July 2007, Silence
    Therapeutics formed a research and development collaboration with
    Astra Zeneca to develop AtuRNAi against five specific targets ($15M
    upfront / equity plus milestone payments of up to $400 million plus
    royalties) in March 2008 and a delivery collaboration. The AtuRNAi
    technology also has been sublicensed to Pfizer (up to $95 million in
    milestone payments) through a collaboration with Quark
    Pharmaceuticals regarding the compound RTP-801i-14 (AtuRNAi) for the
    treatment of Age-related Macular Degeneration (AMD) currently in
    Phase I.

    Company: Vetter Pharma-Fertigung GmbH & Co. KG
    Booth/Stand: 29
    Media Contact: Suzan Frohmann
    Phone: 49 751 3700 0
    E-mail: info@vetter-pharma.com
    Web: www.vetter-pharma.com

    Vetter is an independent international specialist in the production of
    aseptically pre-filled injection systems, cartridges and vials. For
    more than 25 years Vetter has been renowned for its quality,
    innovation and strategic partnerships. The fact that our products and
    processes have been approved by the FDA, the EMEA and other
    authorities ensures the highest level of quality and safety. Vetter
    provides support for its pharmaceutical and biotech clients from the
    initial phases of development and regulatory approval process through
    to the successful product launch and market supply worldwide. Our
    innovative patented application systems will help your product to
    attain a decisive edge in the market.
    *T

    Note to Editors: Business Wire´s PressPass allows you to create
    free, custom Web, RSS, and email-based news feeds from more than 160
    industry options, dozens of subject categories and thousands of
    geographic preferences as well as by specific company filters. In
    addition, PressPass subscribers have access to exclusive content,
    experts, company profiles, email alerts, survey services and other
    media services.

    Note to Event Organizers: Add your trade show, conference, or
    event to http://www.tradeshownews.com, Business Wire´s online event
    calendar. For information, email tradeshow (at) businesswire.com.